{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:10:33Z","timestamp":1768878633617,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s00213-022-06289-0","type":"journal-article","created":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T08:03:27Z","timestamp":1669968207000},"page":"149-156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Valproic acid\u2013induced hyperammonemia in neuropsychiatric disorders: a 2-year clinical survey"],"prefix":"10.1007","volume":"240","author":[{"given":"Helia","family":"Hosseini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahan","family":"Shafie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alia","family":"Shakiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hani","family":"Ghayyem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahsa","family":"Mayeli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matineh","family":"Hassani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1704-323X","authenticated-orcid":false,"given":"Vajiheh","family":"Aghamollaii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,2]]},"reference":[{"issue":"1","key":"6289_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jad.2008.01.024","volume":"111","author":"PF Abraham","year":"2008","unstructured":"Abraham PF, Calabrese JR (2008) Evidenced-based pharmacologic treatment of borderline personality disorder: a shift from SSRIs to anticonvulsants and atypical antipsychotics? J Affect Disord 111(1):21\u201330","journal-title":"J Affect Disord"},{"issue":"2","key":"6289_CR2","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.jhep.2010.11.031","volume":"55","author":"CCP Aires","year":"2011","unstructured":"Aires CCP, van Cruchten A, IJlst L, de Almeida IT, Duran M, Wanders RJA et al (2011) New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA. J Hepatol 55(2):426\u201334","journal-title":"J Hepatol"},{"issue":"2","key":"6289_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00467-011-1838-5","volume":"27","author":"A Auron","year":"2012","unstructured":"Auron A, Brophy PD (2012) Hyperammonemia in review: pathophysiology, diagnosis, and treatment. Pediatr Nephrol 27(2):207\u2013222","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"6289_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.9740\/mhc.2018.03.073","volume":"8","author":"E Baddour","year":"2018","unstructured":"Baddour E, Tewksbury A, Stauner N (2018) Valproic acid\u2013induced hyperammonemia: Incidence, clinical significance, and treatment management. Ment Heal Clin 8(2):73\u20137","journal-title":"Ment Heal Clin"},{"issue":"3","key":"6289_CR5","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/chi.0b013e31802ed8b2","volume":"46","author":"T Carlson","year":"2007","unstructured":"Carlson T, Reynolds CA, Caplan R (2007) Case report: valproic acid and risperidone treatment leading to development of hyperammonemia and mania. J Am Acad Child Adolesc Psychiatry 46(3):356\u201361","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"6289_CR6","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1176\/ajp.2007.164.7.1020","volume":"164","author":"RB Carr","year":"2007","unstructured":"Carr RB, Shrewsbury K (2007) Hyperammonemia due to valproic acid in the psychiatric setting. Am J Psychiatry 164(7):1020\u20137","journal-title":"Am J Psychiatry"},{"issue":"3","key":"6289_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.yebeh.2007.06.015","volume":"11","author":"AV Chicharro","year":"2007","unstructured":"Chicharro AV, de Marinis AJ, Kanner AM (2007) The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist? Epilepsy Behav 11(3):361\u20136","journal-title":"Epilepsy Behav"},{"key":"6289_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.genhosppsych.2019.05.005","volume":"59","author":"B Duman","year":"2019","unstructured":"Duman B, Can KC, A\u011fta\u015f-Ertan E, Erdo\u011fan S, \u0130lhan RS, Do\u011fan \u00d6 et al (2019) Risk factors for valproic acid induced hyperammonemia and its association with cognitive functions. Gen Hosp Psychiatry 59:67\u201372","journal-title":"Gen Hosp Psychiatry"},{"issue":"1","key":"6289_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1212\/WNL.54.1.230","volume":"54","author":"HM Hamer","year":"2000","unstructured":"Hamer HM, Knake S, Schomburg U, Rosenow F (2000) Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 54(1):230","journal-title":"Neurology"},{"issue":"3","key":"6289_CR10","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1176\/appi.neuropsych.10100151","volume":"24","author":"S Holroyd","year":"2012","unstructured":"Holroyd S, Overdyke JT (2012) Hyperammonemia associated with valproic acid use in elderly psychiatric patients. J Neuropsychiatry Clin Neurosci 24(3):372\u20134","journal-title":"J Neuropsychiatry Clin Neurosci"},{"issue":"1","key":"6289_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.genhosppsych.2010.10.004","volume":"33","author":"C-C Hung","year":"2011","unstructured":"Hung C-C, Li T-M, Wei I-H, Huang C-C (2011) The real mechanism of VPA-induced hyperammonemia remains unknown. Gen Hosp Psychiatry 33(1):84-e3","journal-title":"Gen Hosp Psychiatry"},{"issue":"4","key":"6289_CR12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/j.1440-1819.1986.tb03182.x","volume":"40","author":"T Kugoh","year":"1986","unstructured":"Kugoh T, Yamamoto M, Hosokawa K (1986) Blood ammonia level during valproic acid therapy. Psychiatry Clin Neurosci 40(4):663\u20138","journal-title":"Psychiatry Clin Neurosci"},{"key":"6289_CR13","first-page":"34","volume":"57","author":"HK Manji","year":"1996","unstructured":"Manji HK, Chen G, Hsiao JK, Risby ED, Masana MI, Potter WZ (1996) Regulation of signal transduction pathways by mood-stabilizing agents: implications for the delayed onset of therapeutic efficacy. J Clin Psychiatry 57:34\u201346","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"6289_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.9740\/mhc.2021.07.243","volume":"11","author":"T McMorris","year":"2021","unstructured":"McMorris T, Chu A, Vu L, Bernardini A (2021) Hyperammonemia in patients receiving valproic acid in the hospital setting: a retrospective review. Ment Heal Clin 11(4):243\u20137","journal-title":"Ment Heal Clin"},{"issue":"9","key":"6289_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1001\/archneur.1982.00510210061016","volume":"39","author":"JV Murphy","year":"1982","unstructured":"Murphy JV (1982) Asymptomatic hyperammonemia in patients receiving valproic acid. Arch Neurol 39(9):591\u2013592","journal-title":"Arch Neurol"},{"issue":"6","key":"6289_CR16","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/00004714-200212000-00019","volume":"22","author":"M Raja","year":"2002","unstructured":"Raja M, Azzoni A (2002) Valproate-induced hyperammonaemia. J Clin Psychopharmacol 22(6):631\u20133","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"6289_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","volume":"31","author":"MFB Silva","year":"2008","unstructured":"Silva MFB, Aires CCP, Luis PBM, Ruiter JPN, IJlst L, Duran M et al (2008) Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review. J Inherit Metab Dis 31(2):205\u201316","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"6289_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S1474-4422(15)00398-1","volume":"15","author":"T Tomson","year":"2016","unstructured":"Tomson T, Battino D, Perucca E (2016) The remarkable story of valproic acid. Lancet Neurol 15(2):141","journal-title":"Lancet Neurol"},{"issue":"9","key":"6289_CR19","doi-asserted-by":"publisher","first-page":"e0238201","DOI":"10.1371\/journal.pone.0238201","volume":"15","author":"Y-J Tseng","year":"2020","unstructured":"Tseng Y-J, Huang S-Y, Kuo C-H, Wang C-Y, Wang K-C, Wu C-C (2020) Safety range of free valproic acid serum concentration in adult patients. PLoS ONE 15(9):e0238201","journal-title":"PLoS ONE"},{"issue":"4","key":"6289_CR20","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1023\/A:1021918104127","volume":"17","author":"A Verrotti","year":"2002","unstructured":"Verrotti A, Trotta D, Morgese G, Chiarelli F (2002) Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis 17(4):367\u2013373","journal-title":"Metab Brain Dis"},{"issue":"3","key":"6289_CR21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.eplepsyres.2012.04.001","volume":"101","author":"Y Yamamoto","year":"2012","unstructured":"Yamamoto Y, Takahashi Y, Suzuki E, Mishima N, Inoue K, Itoh K et al (2012) Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients. Epilepsy Res 101(3):202\u20139","journal-title":"Epilepsy Res"},{"issue":"6","key":"6289_CR22","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1111\/epi.12125","volume":"54","author":"Y Yamamoto","year":"2013","unstructured":"Yamamoto Y, Takahashi Y, Imai K, Mishima N, Yazawa R, Inoue K et al (2013) Risk factors for hyperammonemia in pediatric patients with epilepsy. Epilepsia 54(6):983\u20139","journal-title":"Epilepsia"},{"issue":"5","key":"6289_CR23","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/bcpt.13049","volume":"123","author":"X Zhu","year":"2018","unstructured":"Zhu X, Li X, Zhang T, Zhao L (2018) Risk factors for valproic acid-induced hyperammonaemia in chinese paediatric patients with epilepsy. Basic Clin Pharmacol Toxicol 123(5):628\u201334","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"6289_CR24","doi-asserted-by":"crossref","unstructured":"Chateauvieux S, Morceau F, Dicato M, Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol. 2010;2010.","DOI":"10.1155\/2010\/479364"},{"key":"6289_CR25","unstructured":"Rosenberg D, Rosenberg DR, Holttum J, Gershon S. Textbook of pharmacotherapy for child and adolescent psychiatric disorders. Psychology Press; 1994."},{"key":"6289_CR26","doi-asserted-by":"crossref","unstructured":"Tseng Y-L, Huang C-R, Lin C-H, Lu Y-T, Lu C-H, Chen N-C, et al (2014) Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy. Medicine 93(11):e66","DOI":"10.1097\/MD.0000000000000066"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06289-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-022-06289-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-022-06289-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,9]],"date-time":"2023-01-09T01:03:06Z","timestamp":1673226186000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-022-06289-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,2]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["6289"],"URL":"https:\/\/doi.org\/10.1007\/s00213-022-06289-0","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,2]]},"assertion":[{"value":"30 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}